

# Guy Bormans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2555301/publications.pdf>

Version: 2024-02-01

167  
papers

9,528  
citations

41344

49  
h-index

43889

91  
g-index

171  
all docs

171  
docs citations

171  
times ranked

10888  
citing authors

#	ARTICLE	IF	CITATIONS
1	The PET tracer [ <sup>11</sup> C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. <i>Science Translational Medicine</i> , 2022, 14, eabg3684.	12.4	10
2	Structure-Based Design, Optimization, and Development of [ <sup>18</sup> F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9034-9049.	6.4	10
3	Improved resolution and sensitivity of [ <sup>18</sup> F]MFBG PET compared with [ <sup>123</sup> I]MIBG SPECT in a patient with a norepinephrine transporter-expressing tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 313-315.	6.4	17
4	Clinical validation of the novel HDAC6 radiotracer [ <sup>18</sup> F]EKZ-001 in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 596-611.	6.4	16
5	Photo isomerization of cis-cyclooctene to trans-cyclooctene: Integration of a microflow reactor and separation by specific adsorption. <i>AIChE Journal</i> , 2021, 67, e17067.	3.6	6
6	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. <i>Nuclear Medicine and Biology</i> , 2021, 93, 19-21.	0.6	43
7	Preclinical evaluation of [ <sup>18</sup> F]cabozantinib as a PET imaging agent in a prostate cancer mouse model. <i>Nuclear Medicine and Biology</i> , 2021, 93, 74-80.	0.6	3
8	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 13.	3.9	1
9	Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. <i>Pharmaceutics</i> , 2021, 13, 599.	4.5	45
10	Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability. <i>Frontiers in Medicine</i> , 2021, 8, 675122.	2.6	8
11	Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets. <i>Bioconjugate Chemistry</i> , 2021, 32, 2052-2064.	3.6	4
12	PET Imaging of Phosphodiesterases in Brain. , 2021, , 851-877.		1
13	Preclinical Evaluation of [ <sup>11</sup> C]YC-72-AB85 for <i>In Vivo</i> Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3915-3927.	3.5	4
14	Preclinical Safety Evaluation and Human Dosimetry of [ <sup>18</sup> F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles. <i>Molecular Imaging and Biology</i> , 2020, 22, 173-180.	2.6	21
15	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 604-607.	5.0	42
16	Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI. <i>Translational Oncology</i> , 2020, 13, 92-101.	3.7	11
17	Reverse engineering synthetic antiviral amyloids. <i>Nature Communications</i> , 2020, 11, 2832.	12.8	25
18	Translation of HDAC6 PET Imaging Using [ <sup>18</sup> F]EKZ-001 – cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1093-1101.	3.5	26

#	ARTICLE	IF	CITATIONS
19	Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients. <i>Journal of Nuclear Medicine</i> , 2020, 61, 256-262.	5.0	24
20	[ <sup>18</sup> F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [ <sup>68</sup> Ga]Ga-DOTATATE in neuroendocrine tumour patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3033-3046.	6.4	59
21	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.	5.0	32
22	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1576-1585.	4.3	47
23	Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe <sub>3</sub> O <sub>4</sub> @Al(OH) <sub>3</sub> nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution. <i>EJNMMI Research</i> , 2020, 10, 73.	2.5	28
24	Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 234-249.	0.7	5
25	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with <sup>18</sup> F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. <i>Journal of Nuclear Medicine</i> , 2019, 60, 107-114.	5.0	92
26	Effects of alcohol exposure on the glutamatergic system: a combined longitudinal <sup>18</sup> F-FPEB and <sup>1</sup> H-MRS study in rats. <i>Addiction Biology</i> , 2019, 24, 696-706.	2.6	17
27	Evaluation of [ <sup>11</sup> C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma. <i>Nuclear Medicine and Biology</i> , 2019, 74-75, 1-11.	0.6	10
28	Design and Challenges of Radiopharmaceuticals. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 339-356.	4.6	76
29	Al <sup>18</sup> F-NOTA-octreotide: first comparison with <sup>68</sup> Ga-DOTATATE in a neuroendocrine tumour patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2398-2399.	6.4	30
30	IC <sub>50</sub> : [ <sup>11</sup> C]MK <sup>6884</sup> PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORS-TREATED AD PATIENTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P121.	0.8	3
31	[ <sup>11</sup> C]JN54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2051-2064.	6.4	55
32	Discovery of <i>N</i> -(4-[( <sup>18</sup> F)Fluoro-5-methylpyridin-2-yl]isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2974-2987.	6.4	24
33	Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging. <i>Nanomaterials</i> , 2019, 9, 1626.	4.1	59
34	Preclinical evaluation of [ <sup>18</sup> F]MA3: a CB <sub>2</sub> receptor agonist radiotracer for PET. <i>British Journal of Pharmacology</i> , 2019, 176, 1481-1491.	5.4	26
35	Evaluation of [ <sup>11</sup> C]NMS-E973 as a PET tracer for <i>in vivo</i> visualisation of HSP90. <i>Theranostics</i> , 2019, 9, 554-572.	10.0	11
36	<sup>18</sup> F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. <i>Journal of Nuclear Medicine</i> , 2019, 60, 683-690.	5.0	63

#	ARTICLE	IF	CITATIONS
37	Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats. <i>Journal of Nuclear Medicine</i> , 2018, 59, 952-959.	5.0	18
38	Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 682-690.	5.0	27
39	The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI- $\mu$ CT microangiography- $\mu$ CT histopathology in rats. <i>International Journal of Cancer</i> , 2018, 143, 1817-1828.	5.1	17
40	Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study. <i>Addiction Biology</i> , 2018, 23, 931-944.	2.6	30
41	Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. <i>Nature Protocols</i> , 2018, 13, 2330-2347.	12.0	27
42	Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers. <i>World Journal of Gastroenterology</i> , 2018, 24, 2710-2721.	3.3	7
43	Somatostatin receptor PET ligands - the next generation for clinical practice. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 311-331.	1.0	55
44	Preclinical Evaluation of $^{18}\text{F}$ -JNJ64349311, a Novel PET Tracer for Tau Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 975-981.	5.0	72
45	cGMP production of the radiopharmaceutical [ $^{18}\text{F}$ ]MK-6240 for PET imaging of human neurofibrillary tangles. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 263-269.	1.0	27
46	Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 943-945.	3.9	9
47	Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 486-496.	6.4	8
48	Cholinergic depletion and basal forebrain volume in primary progressive aphasia. <i>NeuroImage: Clinical</i> , 2017, 13, 271-279.	2.7	22
49	Pretargeted PET Imaging Using a Bioorthogonal $^{18}\text{F}$ -Labeled <i>trans</i> -Cyclooctene in an Ovarian Carcinoma Model. <i>Bioconjugate Chemistry</i> , 2017, 28, 2915-2920.	3.6	38
50	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of $^{11}\text{C}$ -JNJ-42491293, A Novel Radioligand for mGluR2. <i>Journal of Nuclear Medicine</i> , 2017, 58, 110-116.	5.0	31
51	Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels-Alder reactions. Potential applications for pretargeted in vivo PET imaging. <i>Chemical Science</i> , 2017, 8, 1251-1258.	7.4	37
52	[P316]: PRECLINICAL CHARACTERIZATION OF THE NOVEL TAU PET LIGAND [ $^{18}\text{F}$ ]JNJ'067. <i>Alzheimer's and Dementia</i> , 2017, 13, P1069.	0.8	2
53	$^{18}\text{F}$ -Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging. <i>Theranostics</i> , 2017, 7, 2924-2939.	10.0	54
54	Synthesis and preclinical evaluation of [ $^{11}\text{C}$ ]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL). <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 104-113.	5.5	23

#	ARTICLE	IF	CITATIONS
55	Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. <i>Oncotarget</i> , 2017, 8, 55204-55215.	1.8	7
56	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. <i>Frontiers in Pharmacology</i> , 2016, 7, 88.	3.5	22
57	Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer [ <sup>18</sup> F]FPEB in human brain. <i>Synapse</i> , 2016, 70, 153-162.	1.2	18
58	Comparison of New Tau PET-Tracer Candidates With [ <sup>18</sup> F]T808 and [ <sup>18</sup> F]T807. <i>Molecular Imaging</i> , 2016, 15, 153601211562492.	1.4	37
59	Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO <sub>2</sub> : Opportunities for <sup>11</sup> C... <i>Radiochemistry. ChemCatChem</i> , 2016, 8, 3692-3700.	3.7	30
60	[ <sup>18</sup> F]JN42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. <i>Journal of Neurochemistry</i> , 2016, 139, 897-906.	3.9	14
61	De novo design of a biologically active amyloid. <i>Science</i> , 2016, 354, .	12.6	63
62	Guidelines to PET measurements of the target occupancy in the brain for drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2255-2262.	6.4	28
63	Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1436-1441.	5.0	77
64	Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: An [ <sup>18</sup> F]FPEB PET Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1746-1752.	5.0	20
65	Characterization of the novel GlyT1 PET tracer [ <sup>18</sup> F]MK6577 in humans. <i>Synapse</i> , 2015, 69, 33-40.	1.2	17
66	O2-10-03: In vivo characterization of basal forebrain atrophy and cholinergic denervation in primary progressive aphasia. , 2015, 11, P198-P198.		0
67	Retention of [ <sup>18</sup> F]fluoride on reversed phase HPLC columns. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 111, 209-214.	2.8	46
68	Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. <i>Neurobiology of Aging</i> , 2015, 36, 1543-1558.	3.1	75
69	Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. <i>Acta Neuropathologica</i> , 2015, 129, 875-894.	7.7	122
70	Preclinical Evaluation and Quantification of [ <sup>18</sup> F]FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1954-1959.	5.0	21
71	PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. <i>Nuclear Medicine and Biology</i> , 2015, 42, 753-761.	0.6	48
72	Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [ <sup>18</sup> F]MK-9470 PET Study. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 149-158.	8.8	45

#	ARTICLE	IF	CITATIONS
73	PET Imaging of Macrophage Mannose Receptor <sup>18</sup> Expressing Macrophages in Tumor Stroma Using <sup>18</sup> F-Radiolabeled Camelid Single-Domain Antibody Fragments. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1265-1271.	5.0	139
74	Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. <i>Quantitative Imaging in Medicine and Surgery</i> , 2015, 5, 708-29.	2.0	67
75	Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. <i>Neurobiology of Aging</i> , 2014, 35, 2858-2869.	3.1	32
76	Changes in Cerebral CB <sub>1</sub> Receptor Availability after Acute and Chronic Alcohol Abuse and Monitored Abstinence. <i>Journal of Neuroscience</i> , 2014, 34, 2822-2831.	3.6	94
77	In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. <i>European Neuropsychopharmacology</i> , 2014, 24, 242-250.	0.7	51
78	<sup>11</sup> C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists. <i>Journal of Nuclear Medicine</i> , 2014, 55, 65-72.	5.0	23
79	Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5). <i>Nuclear Medicine and Biology</i> , 2014, 41, 155-162.	0.6	16
80	Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. <i>Nuclear Medicine and Biology</i> , 2014, 41, 695-704.	0.6	15
81	PET Radioligands for In Vivo Visualization of Neuroinflammation. <i>Current Pharmaceutical Design</i> , 2014, 20, 5897-5913.	1.9	42
82	Measuring extrastriatal dopamine release during a reward learning task. <i>Human Brain Mapping</i> , 2013, 34, 575-586.	3.6	51
83	Synthesis and biological evaluation of <sup>68</sup> Ga labeled bis-DOTA-3,3'-bis-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3216-3220.	2.2	8
84	Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type 1 receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 207-214.	1.0	3
85	Evaluation of [ <sup>18</sup> F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human. <i>NeuroImage</i> , 2013, 68, 1-10.	4.2	24
86	Synthesis of [ <sup>18</sup> F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin $\alpha_5\beta_3$ expression in vivo. <i>Nuclear Medicine and Biology</i> , 2013, 40, 710-716.	0.6	15
87	Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. <i>NeuroImage</i> , 2013, 79, 304-312.	4.2	93
88	New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation. <i>ACS Chemical Neuroscience</i> , 2013, 4, 624-634.	3.5	12
89	Synthesis and biological evaluation of [ <sup>11</sup> C]SB366791: A new PET-radioligand for in vivo imaging of the TRPV1 receptor. <i>Nuclear Medicine and Biology</i> , 2013, 40, 141-147.	0.6	13
90	Quantification of <sup>18</sup> F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test-Retest Study in Human Brain. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1285-1293.	5.0	43

#	ARTICLE	IF	CITATIONS
91	<sup>18</sup> F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity. Journal of Nuclear Medicine, 2013, 54, 447-454.	5.0	60
92	In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [ <sup>11</sup> C]MK-4232. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 478-486.	2.5	114
93	Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [ <sup>18</sup> F]FDG and [ <sup>18</sup> F]FECT Functional Mapping of the Mouse Brain. PLoS ONE, 2013, 8, e65286.	2.5	16
94	Optimized In Vivo Detection of Dopamine Release Using <sup>18</sup> F-Fallypride PET. Journal of Nuclear Medicine, 2012, 53, 1565-1572.	5.0	49
95	Recent Advances in Positron Emission Tomography (PET) Radiotracers for Imaging Phosphodiesterases. Current Topics in Medicinal Chemistry, 2012, 12, 1224-1236.	2.1	18
96	Pretargeting of necrotic tumors with biotinylated hypericin using <sup>123</sup> I-labeled avidin: evaluation of a two-step strategy. Investigational New Drugs, 2012, 30, 2132-2140.	2.6	14
97	Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging. Journal of Medicinal Chemistry, 2012, 55, 8685-8699.	6.4	48
98	Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. International Journal of Cancer, 2012, 131, E129-37.	5.1	42
99	Interictal Type 1 Cannabinoid Receptor Binding is Increased in Female Migraine Patients. Headache, 2012, 52, 433-440.	3.9	25
100	Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa. Biological Psychiatry, 2011, 70, 777-784.	1.3	78
101	Synthesis, In Vivo Occupancy, and Radiolabeling of Potent Phosphodiesterase Subtype-10 Inhibitors as Candidates for Positron Emission Tomography Imaging. Journal of Medicinal Chemistry, 2011, 54, 5820-5835.	6.4	43
102	A Dual-targeting Anticancer Approach: Soil and Seed Principle. Radiology, 2011, 260, 799-807.	7.3	81
103	Radiolabeling and preliminary biological evaluation of a <sup>99m</sup> Tc(CO) <sub>3</sub> labeled 3,3'-bis-(benzylidene)-bis-(1H-indole-2-carbohydrazide) derivative as a potential SPECT tracer for in vivo visualization of necrosis. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 502-505.	2.2	9
104	A PET Brain Reporter Gene System Based on Type 2 Cannabinoid Receptors. Journal of Nuclear Medicine, 2011, 52, 1102-1109.	5.0	44
105	Optimal buffer choice of the radiosynthesis of <sup>68</sup> Ga- <sup>67</sup> Dotatoc for clinical application. Nuclear Medicine Communications, 2010, 31, 753-758.	1.1	55
106	Influence of Chronic Nicotine Administration on Cerebral Type 1 Cannabinoid Receptor Binding: An In Vivo Micro-PET Study in the Rat Using [ <sup>18</sup> F]MK-9470. Journal of Molecular Neuroscience, 2010, 42, 162-167.	2.3	25
107	In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Research, 2010, 1316, 153-162.	2.2	38
108	<sup>18</sup> F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	5.3	582

#	ARTICLE	IF	CITATIONS
109	99mTc-tricarbonyl labeled agents for cell labeling: Development, biodistribution in normal mice and preliminary in vitro evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 396-402.	3.0	7
110	Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5274-5281.	3.0	25
111	Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding. <i>Synapse</i> , 2010, 64, 617-623.	1.2	13
112	Preclinical Evaluation of <sup>18</sup> F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1584-1591.	5.0	64
113	Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1413-1417.	5.0	107
114	Phase 1 Study of the Pittsburgh Compound B Derivative <sup>18</sup> F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1251-1259.	5.0	273
115	Synthesis and biological evaluation of 11C-labeled $\beta$ -galactosyl triazoles as potential PET tracers for in vivo LacZ reporter gene imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5117-5125.	3.0	12
116	Highly Efficient Multicistronic Lentiviral Vectors with Peptide 2A Sequences. <i>Human Gene Therapy</i> , 2009, 20, 845-860.	2.7	128
117	Synthesis and Evaluation of Three <sup>18</sup> F-Labeled Aminophenylbenzothiazoles as Amyloid Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7090-7102.	6.4	16
118	Synthesis and Evaluation of <sup>18</sup> F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1428-1437.	6.4	87
119	Preliminary in vivo evaluation of a novel 99mTc-Labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3794-3798.	2.2	38
120	In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an $\pm$ 3/ $\pm$ 5 Subtype Selective $\beta$ -Aminobutyric Acid A Partial Agonist. <i>Biological Psychiatry</i> , 2008, 64, 153-161.	1.3	23
121	An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. <i>Neuropharmacology</i> , 2008, 54, 1103-1106.	4.1	34
122	Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [18F]FEET. <i>Nuclear Medicine and Biology</i> , 2008, 35, 75-82.	0.6	18
123	The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake. <i>Cell Metabolism</i> , 2008, 7, 68-78.	16.2	198
124	Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET. <i>NeuroImage</i> , 2008, 39, 1533-1541.	4.2	117
125	Synthesis and Evaluation of <sup>18</sup> F- and <sup>11</sup> C-Labeled Phenyl-Galactopyranosides as Potential Probes for <i>in Vivo</i> Visualization of LacZ Gene Expression using Positron Emission Tomography. <i>Bioconjugate Chemistry</i> , 2008, 19, 441-449.	3.6	43
126	Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand <sup>18</sup> F-MK-9470 in Healthy Subjects. <i>Journal of Nuclear Medicine</i> , 2008, 49, 439-445.	5.0	38



#	ARTICLE	IF	CITATIONS
127	The Presence of Ethanol in Radiopharmaceutical Injections. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2071-2071.	5.0	39
128	[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 9800-9805.	7.1	300
129	Å amyloid deposition in the language system and how the brain responds. <i>Brain</i> , 2007, 130, 2055-2069.	7.6	63
130	Non-invasive imaging of neuropathology in a rat model of $\beta$ -synuclein overexpression. <i>Neurobiology of Aging</i> , 2007, 28, 248-257.	3.1	45
131	Synthesis and evaluation of a $^{99m}\text{Tc}$ -MAMA-propyl-thymidine complex as a potential probe for in vivo visualization of tumor cell proliferation with SPECT. <i>Nuclear Medicine and Biology</i> , 2007, 34, 283-291.	0.6	33
132	Motor- and food-related metabolic cerebral changes in the activity-based rat model for anorexia nervosa: A voxel-based microPET study. <i>NeuroImage</i> , 2007, 35, 214-221.	4.2	42
133	Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin ÅSPECT. <i>European Heart Journal</i> , 2007, 29, 260-269.	2.2	68
134	Necrosis Avidity of $^{99m}\text{Tc}(\text{CO})_3$ -Labeled Pamoic acid Derivatives: Synthesis and Preliminary Biological Evaluation in Animal Models of Necrosis. <i>Bioconjugate Chemistry</i> , 2007, 18, 1924-1934.	3.6	24
135	Evaluation of tumor affinity of mono-[123I]iodohypericin and mono-[123I]iodoprotiohypericin in a mouse model with a RIF-1 tumor. <i>Contrast Media and Molecular Imaging</i> , 2007, 2, 113-119.	0.8	23
136	Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4001-4005.	2.2	24
137	Effect of corticosteroids on $^{18}\text{F}$ -FDG uptake in tumor lesions after chemotherapy. <i>Journal of Nuclear Medicine</i> , 2007, 48, 390-7.	5.0	18
138	Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. <i>Lancet, The</i> , 2006, 367, 113-121.	13.7	1,225
139	The Effect of a Methyl or 2-fluoroethyl Substituent at the N-3 Position of Thymidine, $^3\text{H}$ -fluoro- $^3\text{H}$ -deoxythymidine and $^3\text{H}$ -D-arabinothymine on Their Antiviral and Cytostatic Activity in Cell Culture. <i>Antiviral Chemistry and Chemotherapy</i> , 2006, 17, 17-23.	0.6	8
140	Noninvasive Monitoring of Long-Term Lentiviral Vector-Mediated Gene Expression in Rodent Brain with Bioluminescence Imaging. <i>Molecular Therapy</i> , 2006, 14, 423-431.	8.2	60
141	Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1858-66.	5.0	101
142	Necrosis Avid Contrast Agents. <i>Investigative Radiology</i> , 2005, 40, 526-535.	6.2	82
143	Characterisation and biodistribution of two neutral $^{99m}\text{Tc}(\text{CO})_3$ complexes with a tridentate ligand. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4192-4195.	2.2	7
144	Optimization of geometrical calibration in pinhole SPECT. <i>IEEE Transactions on Medical Imaging</i> , 2005, 24, 180-190.	8.9	61

#	ARTICLE	IF	CITATIONS
145	Development and biological evaluation of <sup>99m</sup> Tc-BAT-tropane esters. <i>Nuclear Medicine and Biology</i> , 2005, 32, 607-612.	0.6	11
146	In vitro evaluation and biodistribution of a <sup>99m</sup> Tc-labeled anti-VEGF peptide targeting neuropilin-1. <i>Nuclear Medicine and Biology</i> , 2004, 31, 575-581.	0.6	48
147	Identity confirmation of <sup>99m</sup> Tc-MAG3, <sup>99m</sup> Tc-Sestamibi and <sup>99m</sup> Tc-ECD using radio-LC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 32, 669-678.	2.8	29
148	Characterization of pinhole SPECT acquisition geometry. <i>IEEE Transactions on Medical Imaging</i> , 2003, 22, 599-612.	8.9	141
149	Accumulation and Photocytotoxicity of Hypericin and Analogs in Two- and Three-Dimensional Cultures of Transitional Cell Carcinoma Cells. <i>Photochemistry and Photobiology</i> , 2003, 78, 607.	2.5	18
150	Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. <i>Blood</i> , 2003, 102, 53-59.	1.4	217
151	Development of a Conjugate of <sup>99m</sup> Tc-EC with Aminomethylenediphosphonate in the Search for a Bone Tracer with Fast Clearance from Soft Tissue. <i>Bioconjugate Chemistry</i> , 2002, 13, 16-22.	3.6	37
152	Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ( <sup>18</sup> F)FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is <sup>18</sup> F)FDG-PET a Valid Alternative to Conventional Diagnostic Methods?. <i>Journal of Clinical Oncology</i> , 2001, 19, 414-419.	1.6	455
153	PET reversed mismatch in an experimental model of subacute myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 457-465.	2.1	14
154	Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p® and carboxymethylcellulose. <i>Journal of Controlled Release</i> , 2000, 68, 207-214.	9.9	57
155	A nonsurgical porcine model of left ventricular dysfunction. Validation of myocardial viability using dobutamine stress echocardiography and positron emission tomography. <i>International Journal of Cardiovascular Interventions</i> , 2000, 3, 111-120.	0.5	4
156	Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-D-glucose in Recurrent Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 894-894.	1.6	221
157	Regional brain activity during shape recognition impaired by a scopolamine challenge to encoding. <i>European Journal of Neuroscience</i> , 1999, 11, 3701-3714.	2.6	33
158	Synthesis of 1-[ <sup>18</sup> F]fluorodeoxyglucose: an unexpected rearrangement in the reaction of 2-O-methanesulfonyl- <sup>12</sup> -D-mannopyranose with [ <sup>18</sup> f] fluoride. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 147-157.	1.0	5
159	Regions in the human brain activated by simultaneous orientation discrimination: a study with positron emission tomography. <i>European Journal of Neuroscience</i> , 1998, 10, 3689-3699.	2.6	34
160	Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1997, 3, 8-17.	3.0	86
161	Attention to One or Two Features in Left or Right Visual Field: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 1997, 17, 3739-3750.	3.6	130
162	Human Brain Activity Related to Orientation Discrimination Tasks. <i>European Journal of Neuroscience</i> , 1997, 9, 246-259.	2.6	55

#	ARTICLE	IF	CITATIONS
163	Myocardial viability and Tc99m-MIBI: Correlation with PET, function and histology. Journal of the American College of Cardiology, 1996, 27, 162.	2.8	0
164	Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Research - Neuroimaging, 1996, 68, 11-22.	1.8	65
165	Regional myocardial blood flow, glucose utilization and contractile function before and after revascularization and ultrastructural findings in patients with chronic coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1299-1305.	2.1	25
166	Metabolism of nitrogen-13 labelled ammonia in different conditions in dogs, human volunteers and transplant patients. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 116-121.	2.1	6
167	Impaired Myocardial Tissue Perfusion Early After Successful Thrombolysis. Circulation, 1995, 92, 2072-2078.	1.6	142